Recommended

New webinar: Overcoming critical challenges in AI-driven drug discovery
Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!
Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucoma
Brand new Beyond the Lab report on antibodies… Download NOW!
article

Assays In-Depth Focus 2020

Posted: 8 September 2020 | | No comments yet

In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer’s disease and a new technology enabling the identification of novel cancer biomarkers.

Assays IDF

    To read this in-depth focus in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *


    *


    *


    *


    *


    *


    *


    *

    This specialist content is provided to you free-of-charge thanks to the kind support of Horizon Discovery


    This in-depth focus includes:

    • Exploring new drug targets in Alzheimer’s disease
      Although many potential targets have been identified for Alzheimer’s disease (AD), there is no effective treatment for this debilitating condition. In this article, Monika Schmidt and Sheraz Gul delve into the key proteins implicated in AD and suggest how phenotypic assays could aid in AD drug discovery.
    • Novel biomarker technology for cancer diagnostics
      A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. Nikki Withers spoke to Professor Carl Borrebaeck, who discusses how the researchers demonstrated the power of combining proteomics with genomics.